How effective is tivozanib treatment?

How effective is tivozanib treatment?

The efficacy and safety of tivozanib have been validated in a large clinical study. This study enrolled 350 patients with metastatic renal cell carcinoma who had previously received at least two lines of therapy that had stopped working (including immunotherapy and other VEGFR-TKIs). Among them, 175 patients were randomly assigned to receive tivozanib, and the other 175 received sorafenib. Direct comparison was made to evaluate the two drugs' effects on controlling tumor growth and spread.

Key Efficacy Data

Results showed that the time without tumor growth or spread was significantly longer in the tivozanib group: median progression-free survival was 5.6 months in the tivozanib group versus 3.9 months in the sorafenib group, representing a 44% increase in disease control time. At one year, 28% of patients (49 patients) in the tivozanib group had no cancer growth or spread, compared to only 11% (19 patients) in the sorafenib group. This indicates that a higher proportion of patients receiving tivozanib achieved long-term stable disease control.

Tumor Shrinkage and Disease Control Rate

Tivozanib also demonstrated better tumor shrinkage effects. Tumor volume shrank in 18% (32 patients) of those taking tivozanib, whereas only 8% (14 patients) of those taking sorafenib experienced tumor shrinkage – more than double the rate. In terms of disease control rate, 73% (128 patients) in the tivozanib group achieved disease control (including stable disease, shrinkage, or complete remission), compared to 65% (114 patients) in the sorafenib group. These data indicate that for patients with metastatic renal cell carcinoma who have failed prior therapies, tivozanib offers superior tumor control and helps delay disease progression.